Up 38% in August, is the Mesoblast share price a buy?

Is there more upside in the Mesoblast limited (ASX: MSB) share price after the ASX biotech share rocketed 38% higher in August?

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price outperformed in August. Shares in the Aussie biotech are up 37.9% in the space of a month after a busy August earnings season. 

Why is the Mesoblast share price rocketing higher?

August was full of market-moving announcements from Mesoblast.

The ASX biotech share plummeted 37.0% in the space of 2 days after a US Food and Drug Administration (FDA) briefing note on one of its products.

The US regulator noted concerns of Mesoblast's remestemcel-L product candidate as a treatment for pediatric steroid-resistant acute graft versus host diseases.

Mesoblast had a meeting with the US Oncologic Drugs Advisory Committee (ODAC) last month as part of its path towards FDA approval.

Those concerns saw the Mesoblast share price crash lower ahead of the meeting before rebounding strongly.

In fact, just days later, the ODAC voted in favour of approving the drug product. Investors piled back into the stock and sent the biotech share soaring to a new 52-week high.

Is it too late to buy Mesoblast?

I think you have to tolerate some risk to invest in ASX biotech shares. The nature of their business can result in volatile share price movements.

The Mesoblast share price closed 37.9% higher in August with a market capitalisation of $3.1 billion.

It's important to remember that we're investing for the long-term here. I think Mesoblast ticks a lot of boxes as a company with a strong product pipeline and promising future earnings.

There will be more volatility over a long enough time horizon. However, it's important to drown out the noise and focus on the potential upside.

Are there other ASX biotech shares to buy?

CSL Limited (ASX: CSL) has proven just how successful Aussie biotech companies can be. Mesoblast has a long way to go before its anywhere near that stratosphere but the early signs are promising.

I'd also consider Polynovo Ltd (ASX: PNV) as a solid buy right now. Polynovo is another ASX biotech share with significant research and development activities and a huge addressable market.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »